Obesity is a serious metabolic disorder that predisposes an individual to multiple pathological conditions like diabetes, renal diseases, gastrointestinal disorders and cancer. According to the World Health Organization (WHO), obesity has more than doubled across nations since 1980. In 2014, >1.9 billion adults (18 years and older) were overweight, and of these over 600 million were obese.
intrOductiOn
Obesity is a serious metabolic disorder that predisposes an individual to multiple pathological conditions like diabetes, renal diseases, gastrointestinal disorders and cancer. According to the World Health Organization (WHO), obesity has more than doubled across nations since 1980. In 2014, >1.9 billion adults (18 years and older) were overweight, and of these over 600 million were obese. [1] Previously considered a problem only in high-income countries, obesity is now dramatically on the rise in low-and middle-income countries. India, a country with 1.2 billion people is currently experiencing rapid epidemiological transition. Undernutrition, due to poverty is being rapidly replaced by obesity associated with affluence. [2] [3] [4] As per the 2007 National Family Health Survey, 12.1% of men and 16% of women are overweight or obese. [5] With an increase in the prevalence of obesity, a parallel surge in obesity-related metabolic disorders like type 2 diabetes (T2D), cardiovascular disease (CVD), hypertension, dyslipidaemia and non-alcoholic fatty liver disease (NAFLD) are being observed. [6] Additionally, inflammation is presently considered a fundamental feature of obesity and T2D. [7] Individuals with normal body weight as per the body mass index (BMI) criteria but with a higher proportion of visceral fat have a proinflammatory cytokine profile similar to obese people.
Though metabolic syndrome (MS) is more common in obese individuals, it does occur in normal weight individuals as well. Studies of inflammatory markers in obese and non-obese people with MS have revealed varying results. The modest sample size of the study populations, and selective enrolment of women and older men are some of the reasons behind these diverse findings. [8, 9] However, despite its apparent clinical significance, not many studies have assessed the relationship between inflammatory cytokines and various components of MS. [10] [11] [12] [13] We therefore undertook the present study to analyse the inflammatory markers in obese and non-obese patients with MS and to assess the correlation between inflammatory cytokines and components of MS.
MateriaLS and MethOdS

Subject population
Present work is an observational cross-sectional study carried out at the Department of Endocrinology, in a tertiary care centre in north India between October 2014 and June 2016. The study was approved by the Institutional Ethical Committee (IEC) and an informed consent was obtained from all participants. A total of 76 individuals were included in the study, out of which 37 were obese (Group A) and 39 non-obese (Group B). Each recruited individual was interviewed and examined as per a predefined protocol. Only adult subjects (18 years or older) with MS with or without obesity were included in the study. Patients with chronic kidney disease, overt CVD, chronic liver disease, malignancy, acute or chronic inflammatory or infectious disease and autoimmune disorders were not included in the study. Furthermore, diabetic patients on insulin also were excluded from the study.
Anthropometry
Height and weight were measured as per the standard recommendations; BMI was calculated as weight in kg divided by height in m 2 , waist circumference (WC) was measured with the help of non-stretchable measurement tape at the level just above the iliac crest at the end of expiration and hip circumference was measured at the widest point. [14] An individual was considered obese if his/her BMI was >25 kg/m 2 . [15] For the diagnosis of MS, the National Cholesterol Education Program (NCEP-ATP III) criteria were used, namely three or more of the following: abdominal obesity (WC ≥102 cm in men and ≥88 cm in women), hypertriglyceridaemia (≥150 mg/dl), low high-density lipoprotein (HDL <40 mg/dl in men and <50 mg/dl in women), hypertension (BP >130/85 mm Hg or on treatment) and fasting glucose (>110 mg/dl). [16] Normal weight individuals with MS were further subdivided into two groups based on the presence of abdominal obesity (WC cut-off 90 cm for men and 80 cm for women). [17] 
Biochemical and cytokine evaluation
After an overnight fast, a venous blood sample was drawn for investigations like haemogram, kidney and liver function, fasting blood glucose and lipid profile.
Serum was separated within 1 h, and preserved at −80°C for the estimation of cytokines [tumour necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and adiponectin]. Plasma IL-6, TNF-α and adiponectin concentrations were measured with a high-sensitivity enzyme-linked immunosorbent assay (ELISA) for human TNF-α, IL-6 and adiponectin. ELISA for TNF-α was performed by the Diaclone TNF-α ELISA kit (Diaclone SAS, Besancon Cedex, France); the overall coefficient of variation was 3.3%. ELISA for IL-6 was performed by the Diaclone IL-6 ELISA kit (Diaclone SAS, Besancon Cedex, France); the overall coefficient of variation was 4.2%. ELISA for adiponectin was performed by the BioVender adiponectin kit (BioVender, Karasek, Czech Republic); the coefficient of variation was 3.9% for intra-assay and 6.3% for inter-assay.
Statistical analysis
The statistical software SPSS Version 20 (IBM SPSS Statistics for Windows, Version 20 Armonk, NY: IBM Corp) was used to analyse the data. The normality of the distribution of each variable was tested. Data were expressed as mean ± SD for normally distributed variables. Logarithmic transformations were applied to TNF-α and IL-6. The Pearson correlation coefficient was used to quantify the univariate associations between variables. The unpaired Students t-test was used to compare mean values between different groups. All the results have been described on 5% level of significance, i.e., P value <0.05 considered as significant.
reSuLtS
Seventy six patients (44 men and 32 women) with MS as per the NCEP-ATP III criteria were included in this study. These patients were further subdivided into obese and non-obese based on the BMI. Those having BMI of ≤25 kg/m 2 were considered as non-obese, while those with BMI >25 kg/m 2 were considered as obese. The lipid parameters and liver enzymes did not differ significantly in obese and non-obese patients, though fatty liver was commoner in former. There were no significant differences in the levels of TNF-α, IL-6 and adiponectin between obese and non-obese patients with MS [ Table 1 ]. Results of cytokine analysis also revealed that levels of TNF-α, IL-6 and adiponectin were not different among non-obese patients with or without abdominal obesity [ Table 2 ]. No significant correlation was found between the cytokine levels and different parameters of MS [ Table 3 ].
diScuSSiOn
MS represents clustering of multiple CVD risk factors within an individual. NCEP-ATP III criteria are commonly used for the diagnosis of MS because of their ease of use in clinical settings. [18] Though obesity is an important constituent of MS with clustering of cardiovascular risk factors, such risk factors are also seen in some normal weight individuals often referred to as 'metabolically obese normal weight individuals' (MONW). [19] Chronic low-grade inflammation invariably accompanies MS and is associated with adverse proinflammatory cytokine profile both in serum and adipose tissue. [20] In the current study, the obese MS patients were more often female and were younger than the non-obese MS patients. This could be a referral bias that young people with obesity seek medical attention earlier. Moreover, in developing countries, young people are gaining weight because of changes in lifestyle and food habits. [21] The female preponderance in the current study could be a true reflection of increased prevalence of MS in women in India. A recent study from India demonstrated that 29% of women had MS as against 26% of men. [22] Data from the National Health and Nutrition Examination Survey (NHANES) also revealed a progressive rise in abdominal obesity in both men and women between 1988 and 1999 with overall prevalence of abdominal obesity progressively increasing in women from 46% in 1988 to 58% in 1999; despite normal body weight, abdominal obesity was present in 80% females and 47% males in the non-obese group. [23] A study from US revealed that among non-obese (BMI <25) individuals, 19.6% of women had increased WC, while <2% men had increased WC. [19] In recent studies, WC has been documented as an important clinical risk parameter predicting the presence of obesity and fatty liver. [24, 25] The present study also demonstrates a strong correlation between WC and BMI (r = 0.84, P < 0.001). Also we found a strong correlation between WC and fatty liver (r = 0.30, P < 0.001). Though fatty liver was prevalent in 72% of patients in obese group compared to 38% in non-obese group, in the latter group it was more often seen in those with abdominal obesity. Previous studies have shown that increase in WC can reliably predict the risk of NAFLD in obese adolescents. [26] Acanthosis nigricans (AN), a reliable marker of insulin resistance (IR) and an independent risk factor for the development of diabetes mellitus, is commonly associated with MS. [27, 28] Our results revealed that AN was more common in obese patients than normal weight individuals and it correlated with weight, BMI and WC.
Adverse cardiovascular risk factors like high, low-density lipoprotein (LDL) and low HDL were seen in both obese and non-obese patients with MS. Though half of our patients with MS were non-obese as per the BMI criteria, abdominal obesity was present in majority of these patients. There was no significant difference in lipid parameters like TC, TG, HDL and LDL between obese and non-obese group. Abdominal obesity has been found to have significant association with adverse lipid profile. [29] A recent study demonstrated that, in MONW people, dyslipidaemia was seen in 30%. [19] The adiposity associated with IR leads to an increased lipolysis causing increased free fatty acid delivery to liver resulting in fatty liver disease. [30] Our results also showed that elevated serum TG or free fatty acids strongly correlated with the presence of fatty liver.
TNF-α; a proinflammatory cytokine is elevated in various pathophysiological conditions in adipose tissues, if given exogenously, TNF-α causes IR. [31] [32] [33] [34] [35] Our study demonstrated a high prevalence of elevated TNF-α in patients with MS, though there was no statistically significant difference between obese and non-obese group There was no correlation between TNF-α and other components of MS, however, a strong correlation between TNF-α and another inflammatory marker IL-6 was seen (r = 0.654, P < 0.001). In recent past, Phillips and Perry reported significantly higher levels of TNF-α in both obese and lean people with MS as compared with metabolically healthy individuals, [36] similar findings were reported in people with diabetes in whom the levels of TNF-α progressively increased with increase in IR. [37] In addition to obese women, inflammatory cytokine like TNF-α has been found to be increased in normal weight women with body fat in excess of 30% (a condition defined as normal weight obese) compared with normal weight controls.
[38] However, Rajkovic et al., demonstrated high level of TNF-α in obese, overweight and lean people with diabetes, moreover, significantly higher levels were seen in obese/overweight patients compared with lean patients. [39] Numerous studies reported increased levels of IL-6 in patients with MS and T2D. IL-6 is one of the earliest cytokines to be associated with IR, CVD and CV mortality, and it also plays an important role in hepatic IR. [40, 41] The recently reported finding that visceral fat secretes more IL-6 than the subcutaneous fat may partly underlie with high (risk of) IR from abdominal obesity. [42] Our study showed IL-6 levels to be significantly higher in both obese and non-obese patients with MS. There was a significant correlation between TNF-α and IL-6 level (r = 0.654, P < 0.001). Levels of IL-6 were not significantly associated with any other component of MS.
Goyal et al. also found high levels of IL-6 in both lean and obese individuals with T2D compared with controls. [43] In agreement with our finding Phillips and Perry also found significantly higher IL-6 levels in metabolically unhealthy individuals irrespective of body weight. [36] Another study comprising a small cohort of elderly people, found higher IL-6 levels in obese patients with T2D compared with controls. Possibly a small sample size and advanced age of the population could have affected the results. [39] In a study of British population, level of IL-6 strongly correlated with body weight and WC. [8] Difference in ethnicity could be responsible for the variation from our results.
An anti-inflammatory cytokine adiponectin is an adipocyte-derived hormone which reduces IR in muscle and fat and improves insulin sensitivity when administered exogenously. [44, 45] Adiponectin in the present study was significantly lower in patients with MS irrespective of weight and correlated negatively with clinical parameters like waist hip ratio and biochemical parameters like serum TG levels. Phillips and Perry also showed significantly decreased adiponectin levels in patients with MS irrespective of body weight as compared with controls. [36] Another study also revealed a significant decline in adiponectin in patients with T2D compared with controls and the difference decreased in patients with IR without T2D compared with controls. [46] In agreement with our study, no correlation was found between parameters of fatness and adiponectin level. [46] An inverse correlation was also found between adiponectin, TC and TG by Tamang et al. [47] Another study revealed a significant negative correlation between adiponectin and weight, BMI, fat mass, adverse lipid levels like TC and TG and a positive correlation with serum HDL levels. [9] The study consisted of a small sample size of patients with more pronounced obesity.
cOncLuSiOn
A significant proportion of individuals categorised as normal weight were found to have an increased WC which significantly correlated with BMI, AN and fatty liver. Despite differences in BMI and WC, there was no significant difference in various metabolic and inflammatory parameters between obese and non-obese patients with MS. Even in non-obese group, no difference in metabolic and inflammatory markers was observed between individuals with or without abdominal obesity. This finding indicates that apart from adipose tissue, other factors could also be responsible for the development of MS and its associated proinflammatory profile. There could be a significant contribution of genetic and epigenetic factors which needs to be further explored. 
